Table 2.
Percentage of pharmacists’ knowledge about EBM terms
| EBM Knowledge Term | Do not understand and not willing to learn | Do not understand but would like to learn | Some understanding | Understand and could explain to others |
|---|---|---|---|---|
| Relative risk | 4 (2.3%) | 29 (16.8%) | 82 (47.4%) | 58 (33.5%) |
| Absolute risk | 5 (2.9%) | 32 (18.5%) | 62 (35.8%) | 74 (42.8%) |
| Systematic review | 5 (2.9%) | 55 (32.0%) | 68 (39.5%) | 44 (25.6%) |
| Odds ratio | 6 (3.5%) | 80 (46.5%) | 59 (34.3%) | 27 (15.7%) |
| Meta-analysis | 8 (4.7%) | 76 (44.7%) | 54 (31.8%) | 32 (18.8%) |
| Clinical effectiveness | 4 (2.3%) | 25 (14.5%) | 74 (42.8%) | 70 (40.4%) |
| Sample size calculation | 3 (1.7%) | 43 (24.9%) | 76 (43.9%) | 51 (29.5%) |
| Confidence interval | 3 (1.8%) | 69 (42.1%) | 61 (37.2%) | 31 (18.9%) |
| P-value | 7 (4.1%) | 73 (42.9%) | 54 (31.8%) | 36 (21.2%) |
| Heterogeneity | 9 (5.3%) | 69 (40.6%) | 56 (32.9%) | 36 (21.2%) |
| Publication bias | 7 (4.2%) | 68 (40.5%) | 48 (28.6%) | 45 (26.7%) |
| Sensitivity | 4 (2.3%) | 48 (28.1%) | 58 (33.9%) | 61 (35.7%) |
All of the socio-demographic variables were not significantly associated with EBM knowledge scores (p ≥ 0.05), except for the item “previous exposure to EBM” (p = 0.001).